Our third program, X4P-002, is a unique series of late lead molecules that selectively antagonize CXCR4 and penetrate the blood brain barrier. We intend to select the final drug candidate by early 2017 to enable early clinical development against glioblastoma multiforme (GBM), a lethal type of brain cancer in 2018.
The CXCR4 receptor has been shown to be differentially expressed at the leading edge of GBM cancer infiltration and increased expression of CXCR4 has been correlated with increased mortality rates. CXCL12 is highly expressed in brain tumors and along the vascaluture of the brain. Additionally in pre-clinical animal models of GBM, CXCR4 antagonism has demonstrated a major survival benefit in combination with radiation.